Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2024 - Issue 2

Divergences in Antiviral Therapy for Diabetic Patients with COVID-19 Download PDF


, , , , , , ,
  1. Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410087, Romania.
  2. Department of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410073, Romania.
  3. Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410028, Romania.
  4. Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410073, Romania.
  5. Department of Surgical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410073, Romania.
Abstract

Patients with diabetes are particularly susceptible to COVID-19 infection, which can result in severe respiratory illness. This study conducted a comparative assessment of the impact of antiviral therapy using molnupiravir and favipiravir in COVID-19 patients with underlying diabetes. A cohort of one hundred individuals infected with SARS-CoV-2, diagnosed with diabetes, and consecutively admitted, was included in the present study. These patients were treated with antivirals according to local guidelines: Group F (51 cases) was treated with favipiravir – 10 days and Group M (49 cases) was treated with molnupiravir – 5 days. In Group F, the average hospitalization was higher than in Group M (11.29±2.27 vs. 7.14±3.16, p<0.001). The risk score for severe evolution was less statistically significant at the end point of treatment in group M (156.29±61.32; 160.59±59.41, p<0.001). Administration of molnupiravir led to a decrease in the number of deaths among patients with COVID-19 compared to those treated with favipiravir [2 (4.08%) vs. 9 (17.65%), p=0.034]. Molnupiravir demonstrated superiority over favipiravir in treating SARS-CoV-2 infection in diabetic patients, and controlling or diagnosing diabetes is crucial to prevent the critical progression of COVID-19 patients. Further research is needed to confirm its potential in the management of infected individuals with SARS-CoV-2.

Cite this article
Vancouver
Fitero A, Negruț N, Cseppento DCN, Tit DM, Negru PA, Bustea C, et al. Divergences in Antiviral Therapy for Diabetic Patients with COVID-19. Pharmacophore. 2024;15(2):79-89. https://doi.org/10.51847/pERPVY0am7
APA
Fitero, A., Negruț, N., Cseppento, D. C. N., Tit, D. M., Negru, P. A., Bustea, C., Radu, A. F., & Bungau, S. G. (2024). Divergences in Antiviral Therapy for Diabetic Patients with COVID-19. Pharmacophore, 15(2), 79-89. https://doi.org/10.51847/pERPVY0am7

Related articles:
Most viewed articles:
QR code:

Short Link:
Views: 503

Downloads: 101
Quick Access

Associations

Pharmacophore
ISSN: 2229-5402

Copyright © 2024 Pharmacophore. Authors retain copyright of their article if they are accepted for publication.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.